特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
927169

リキッドパイオプシーの世界市場予測:~2029年

Global Liquid Biopsy Market Forecast to 2029

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=143.80円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

リキッドパイオプシーの世界市場予測:~2029年
出版日: 2019年11月29日
発行: Visiongain Ltd
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のリキッドパイオプシー (液体生検) 市場規模は、2019年に11億7,350万米ドルへ達しました。キット & 試薬セグメントは世界のリキッドパイオプシー市場において最大のシェアを構成しています。

当レポートでは、当レポートでは、世界のリキッドパイオプシー (液体生検) 市場について調査し、市場の概要とセグメント別、地域別動向、および市場に参入する企業のプロファイルなど体系的な情報を提供しています。

第1章 レポートの概要

第2章 リキッドパイオプシー市場の概要

  • リキッドパイオプシーの歴史
  • リキッドパイオプシーのメリット
  • リキッドパイオプシー市場の動向
  • 市場ダイナミクス
  • 世界のリキッドパイオプシー市場:収益予測
  • リキッドパイオプシーの規制環境
  • リキッドパイオプシー産業における近年の発展

第3章 世界のリキッドパイオプシー市場予測:製品タイプ別

  • 世界市場:製品タイプ別・収益予測
  • 機器セグメントの収益予測
  • キット・試薬セグメントの収益予測
  • サービスセグメントの収益予測
  • 市場シェア分析:製品タイプ別

第4章 世界のリキッドパイオプシー市場:サンプルタイプ別

  • 世界市場:サンプルタイプ別・収益予測
  • 血液サンプルセグメントの収益予測
  • 尿サンプルセグメントの収益予測
  • その他サンプルセグメントの収益予測
  • 市場シェア分析:サンプルタイプ別

第5章 世界のリキッドパイオプシー市場:バイオマーカータイプ別

  • 世界市場:バイオマーカータイプ別・収益予測
  • 循環腫瘍細胞(CTC)セグメントの収益予測
  • 循環腫瘍DNA(ctDNA)セグメントの収益予測
  • その他バイオマーカーセグメントの収益予測
  • 市場シェア分析:バイオマーカータイプ別

第6章 世界のリキッドパイオプシー市場:癌タイプ別

  • 世界市場:癌タイプ別・収益予測
  • 乳癌セグメントの収益予測
  • 大腸癌セグメントの収益予測
  • 肝臓癌セグメントの収益予測
  • 肺癌セグメントの収益予測
  • 前立腺癌セグメントの収益予測
  • その他の癌セグメントの収益予測
  • 癌タイプ別市場シェア分析
  • 癌の発生率の比較:地域別
  • 地域を越えた乳癌の発生パターン

第7章 世界のリキッドパイオプシー市場:エンドユーザー別

  • 世界市場:エンドユーザー別・収益予測
  • 病院セグメントの収益予測
  • 診断ラボセグメントの収益予測
  • 大学機関セグメントの収益予測
  • 癌研究センターセグメントの収益予測
  • 市場シェア分析:エンドユーザー別

第8章 主要国市場

  • 収益予測:主要国別
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ

第9章 主要企業

  • 企業ランキング
  • Menarini Silicon Biosystems, Inc.
  • MDxHealth SA
  • Biocept, Inc.
  • Trovagene, Inc.
  • Sysmex Inostics GmbH (A Subsidiary of Sysmex Corporation)
  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Biotime (Oncocyte Corporation)
  • Abbott
  • Beckman Coulter (Danaher Corporation)
  • Caris Life Sciences
  • OPKO Health, Inc.

第10章 定性分析

  • PESTEL分析

第11章 結論

図表

List of Tables

  • Table 2.1: Global Liquid Biopsy Market, Revenue ($mn) and AGR (%) 2018-2029
  • Table 3.1: Global Liquid Biopsy Market, By Product Type, Revenue ($mn), AGR (%) and CAGR (%) 2018-2029
  • Table 3.2: Global Liquid Biopsy Market, Instruments Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 3.3: Global Liquid Biopsy Instruments Market, Region Segment Revenue ($m), 2017-2029
  • Table 3.4: Global Liquid Biopsy Market, Kits & Reagents Segment Revenue ($m), AGR (%) and CAGR (%) 2017-2029
  • Table 3.5: Global Liquid Biopsy Kits & Reagents Market, Region Segment Revenue ($m), 2018-2029
  • Table 3.6: Global Liquid Biopsy Market, Services Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 3.7: Global Liquid Biopsy Services Market, Region Segment Revenue ($m), 2018-2029
  • Table 3.8: Global Liquid Biopsy Market, Revenue ($m), Revenue Share (%) by Product Type, 2018, 2024, 2029
  • Table 4.1: Global Liquid Biopsy Market, By Sample Type, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 4.2: Global Liquid Biopsy Market, Blood Sample Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 4.3: Global Liquid Biopsy Blood Sample Market, Region Segment Revenue ($m), 2018-2029
  • Table 4.4: Global Liquid Biopsy Market, Urine Sample Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 4.5: Global Liquid Biopsy Urine Sample Market, Region Segment Revenue ($m), 2018-2029
  • Table 4.6: Global Liquid Biopsy Market, Other Samples Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 4.7: Global Liquid Biopsy Other Sample Market, Region Segment Revenue ($m), 2018-2029
  • Table 4.8: Global Liquid Biopsy Market, Revenue ($m), Revenue Share (%) by Sample Type, 2018, 2024, 2029
  • Table 5.1: Global Liquid Biopsy Market, By Biomarker Type, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 5.2: Global Liquid Biopsy Market, Circulating Tumour Cell (CTC) Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 5.3: Global Liquid Biopsy Circulating Tumour Cell (CTC) Biomarker Market, Region Segment Revenue ($m), 2018-2029
  • Table 5.4: Global Liquid Biopsy Market, Circulating Tumour DNA (ctDNA) Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 5.5: Global Liquid Biopsy Circulating Tumour DNA (ctDNA) Biomarker Market, Region Segment Revenue ($m), 2018-2029
  • Table 5.6: Global Liquid Biopsy Market, Exosomes Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 5.7: Global Liquid Biopsy Exosomes Biomarker Market, Region Segment Revenue ($m), 2018-2029
  • Table 5.8: Global Liquid Biopsy Market, Other Biomarkers Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 5.9: Global Liquid Biopsy Other Biomarkers Market, Region Segment Revenue ($m), 2018-2029
  • Table 5.10: Global Liquid Biopsy Market, Revenue ($m), Revenue Share (%) by Biomarker Type, 2018, 2024, 2029
  • Table 6.1: Global Liquid Biopsy Market, By Cancer Type, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 6.2: Global Liquid Biopsy Market, Breast Cancer Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 6.3: Global Liquid Biopsy Breast Cancer Market, Region Segment Revenue ($m), 2018-2029
  • Table 6.4: Global Liquid Biopsy Market, Colorectal Cancer Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 6.5: Global Liquid Biopsy Colorectal Cancer Market, Region Segment Revenue ($m), 2018-2029
  • Table 6.6: Global Liquid Biopsy Market, Liver Cancer Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 6.7: Global Liquid Biopsy Liver Cancer Market, Region Segment Revenue ($m), 2018-2029
  • Table 6.8: Global Liquid Biopsy Market, Lung Cancer Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 6.9: Global Liquid Biopsy Lung Cancer Market, Region Segment Revenue ($m), 2018-2029
  • Table 6.10: Global Liquid Biopsy Market, Prostate Cancer Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 6.11: Global Liquid Biopsy Prostate Cancer Market, Region Segment Revenue ($m), 2018-2029
  • Table 6.12: Global Liquid Biopsy Market, Other Cancers Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 6.13: Global Liquid Biopsy Other Cancer Market, Region Segment Revenue ($m), 2018-2029
  • Table 6.14: Global Liquid Biopsy Market, Revenue ($m), Revenue Share (%) by Cancer Type, 2018, 2024, 2029
  • Table 7.1: Global Liquid Biopsy Market, By End User, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 7.2: Global Liquid Biopsy Market, Hospitals Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 7.3: Global Liquid Biopsy Hospitals Market, Region Segment Revenue ($m), 2018-2029
  • Table 7.4: Global Liquid Biopsy Market, Diagnostic Laboratories Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 7.5: Global Liquid Biopsy Diagnostic Laboratories Market, Region Segment Revenue ($m), 2018-2029
  • Table 7.6: Global Liquid Biopsy Market, Academic Institutions Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 7.7: Global Liquid Biopsy Academic Institutions Market, Region Segment Revenue ($m), 2018-2029
  • Table 7.8: Global Liquid Biopsy Market, Cancer Research Centres Segment Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 7.9: Global Liquid Biopsy Cancer Research Centres Market, Region Segment Revenue ($m), 2018-2029
  • Table 7.10: Global Liquid Biopsy Market, Revenue ($m), Revenue Share (%) by End User, 2018, 2024, 2029
  • Table 8.1: Global Liquid Biopsy Market, Revenue ($m), Revenue Share (%) by Leading Nationals, 2018, 2024, 2029
  • Table 8.2: Global Liquid Biopsy Market, By Leading Nationals, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.3: North America Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.4: North America Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%), By Country 2018-2029
  • Table 8.5: US Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.6: Canada Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.7: Mexico Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.8: Europe Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.9: Europe Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%), By Country 2017-2028
  • Table 8.10: Germany Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.11: France Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.12: United Kingdom Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.13: Italy Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.14: Spain Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.15: Russia Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.16: Asia-Pacific Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.17: Asia-Pacific Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%), By Country 2018-2029
  • Table 8.18: Japan Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.19: China Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 8.20: Australia Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 8.21: South Korea Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.22: India Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.23: LAMEA Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 8.24: LAMEA Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%), By Country 2018-2029
  • Table 8.25: Brazil Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 8.26: Turkey Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 8.27: Venezuela Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.28: Saudi Arabia Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 8.29: Republic of South Africa Liquid Biopsy Market, Revenue ($m), AGR (%) and CAGR (%) 2018-2029
  • Table 9.1: Silicon Biosystems Product Portfolio
  • Table 9.2: Silicon Biosystems Recent Developments
  • Table 9.3: MDxHealth SA Financials ($m), 2015-2017
  • Table 9.4: MDxHealth SA Product Portfolio
  • Table 9.5: MDxHealth SA Recent Developments
  • Table 9.6: Biocept Financials ($thousand), 2014-2016
  • Table 9.7: Biocept Product Portfolio
  • Table 9.8: Biocept Recent Developments
  • Table 9.9: Trovagene, Inc. Financials ($thousand), 2015-2017
  • Table 9.10: Trovagene, Inc. Product Portfolio
  • Table 9.11: Trovagene, Inc. Recent Developments
  • Table 9.12: Sysmex Inostics Product Portfolio
  • Table 9.13: Sysmex Inostics Financials ($m), 2015-2017
  • Table 9.14: Sysmex Inostics GmbH Recent Developments
  • Table 9.15: Roche Financials ($m), 2015-2017
  • Table 9.16: Roche Product Portfolio
  • Table 9.17: Roche Recent Developments
  • Table 9.18: Bio-Rad Financials ($m), 2014-2016
  • Table 9.19: Bio-Rad Product Portfolio
  • Table 9.20: Bio-Rad Recent Developments
  • Table 9.21: Guardant Product Portfolio
  • Table 9.22: Guardant Recent Developments
  • Table 9.23: Illumina Financials ($m), 2014-2016
  • Table 9.24: Illumina (GRAIL) Recent Developments
  • Table 9.25: Myriad Financials ($m), 2015-2017
  • Table 9.26: Myriad Product Portfolio
  • Table 9.27: Myriad Recent Developments
  • Table 9.28: Qiagen Financials ($m), 2015-2017
  • Table 9.29: Qiagen Product Portfolio
  • Table 9.30: Qiagen Recent Developments
  • Table 9.31: Biotime (Oncocyte Corporation) Financials ($m), 2015-2017
  • Table 9.32: Biotime (Oncocyte Corporation) Product Portfolio
  • Table 9.33: Abbott Financials ($m), 2015-2017
  • Table 9.34: Abbott Recent Developments
  • Table 9.35: Beckman Coulter (Danaher Corporation) Financials ($m), 2015-2017
  • Table 9.36: Beckman Coulter Product Portfolio
  • Table 9.37: Beckman Coulter Recent Developments
  • Table 9.38: Caris Life Sciences Product Portfolio
  • Table 9.39: OPKO Health, Inc. Financials ($m), 2015-2017
  • Table 9.40: OPKO Health, Inc. Product Portfolio
  • Table 9.41: OPKO Health, Inc. Recent Developments

List of Figures

  • Figure 2.1 Ageing Population Estimates 2010 - 2050
  • Figure 2.2: Global Liquid Biopsy Market Revenue ($mn), 2018-2029
  • Figure 2.3: Latest trends in liquid biopsy
  • Figure 3.1: Global Liquid Biopsy Market Revenue ($m), By Product Type, 2018-2029
  • Figure 3.2: Global Liquid Biopsy Market, Instruments Segment Revenue ($m), 2018-2029
  • Figure 3.3: Global Liquid Biopsy Market, Kits & Reagents Segment Revenue ($m), 2018-2029
  • Figure 3.4: Global Liquid Biopsy Market, Services Segment Revenue ($m), 2018-2029
  • Figure 4.1: Global Liquid Biopsy Market Revenue ($m), By Sample Type, 2017-2029
  • Figure 4.2: Global Liquid Biopsy Market, Blood Sample Segment Revenue ($m), 2018-2029
  • Figure 4.3: Global Liquid Biopsy Market, Urine Sample Segment Revenue ($m), 2018-2029
  • Figure 4.4: Global Liquid Biopsy Market, Other Samples Segment Revenue ($m), 2018-2029
  • Figure 5.1: Global Liquid Biopsy Market Revenue ($m), By Biomarker Type, 2018-2029
  • Figure 5.2: Global Liquid Biopsy Market, Circulating Tumour Cell (CTC) Segment Revenue ($m), 2018-2029
  • Figure 5.3: Global Liquid Biopsy Market, Circulating Tumour DNA (ctDNA) Segment Revenue ($m), 2018-2029
  • Figure 5.4: Global Liquid Biopsy Market, Exosomes Segment Revenue ($m), 2018-2029
  • Figure 5.5: Global Liquid Biopsy Market, Other Biomarkers Segment Revenue ($m), 2018-2029
  • Figure 6.1: Global Liquid Biopsy Market Revenue ($m), By Cancer Type, 2018-2029
  • Figure 6.2: Global Liquid Biopsy Market, Breast Cancer Segment Revenue ($m), 2018-2029
  • Figure 6.3: Global Liquid Biopsy Market, Colorectal Cancer Segment Revenue ($m), 2018-2029
  • Figure 6.4: Global Liquid Biopsy Market, Liver Cancer Segment Revenue ($m), 2018-2029
  • Figure 6.5: Global Liquid Biopsy Market, Lung Cancer Segment Revenue ($m), 2018-2029
  • Figure 6.6: Global Liquid Biopsy Market, Prostate Cancer Segment Revenue ($m), 2018-2029
  • Figure 6.7: Global Liquid Biopsy Market, Other Cancers Segment Revenue ($m), 2018-2029
  • Figure 6.8: Cancer Mortalities Across Geographies, 2018
  • Figure 6.9: Cancer Incidence Across Geographies, 2018
  • Figure 6.10: Cancer Incidence vs Mortality Scenario Across Geographies, 2018
  • Figure 6.11: New cases of breast cancer at different age groups, 2015
  • Figure 6.12: New cases of breast cancer at different age groups, 2016
  • Figure 7.1: Global Liquid Biopsy Market Revenue ($m), By End User, 2018-2029
  • Figure 7.2: Global Liquid Biopsy Market, Hospitals Segment Revenue ($m), 2018-2029
  • Figure 7.3: Global Liquid Biopsy Market, Diagnostic Laboratories Segment Revenue ($m), 2018-2029
  • Figure 7.4: Global Liquid Biopsy Market, Academic Institutions Segment Revenue ($m), 2018-2029
  • Figure 7.5: Global Liquid Biopsy Market, Cancer Research Centres Segment Revenue ($m), 2018-2029
  • Figure 8.1: Global Liquid Biopsy Market Revenue ($m), by Leading Nationals, 2018-2029
  • Figure 8.2: North America Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.3: US Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.4: Canada Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.5: Mexico Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.6: Europe Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.7: Germany Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.8: France Liquid Biopsy Market, Revenue ($m), 2017-2029
  • Figure 8.9: United Kingdom Liquid Biopsy Market, Revenue ($m), 2017-2029
  • Figure 8.10: Italy Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.11: Spain Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.12: Russia Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.13: Asia-Pacific Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.14: Japan Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.15: China Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.16: Australia Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.17: South Korea Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.18: India Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.19: LAMEA Liquid Biopsy Market, Revenue ($m), 2017-2028
  • Figure 8.20: Brazil Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.21: Turkey Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.22: Venezuela Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.23: Saudi Arabia Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 8.24: Republic of South Africa Liquid Biopsy Market, Revenue ($m), 2018-2029
  • Figure 9.1 Top Companies in Liquid Biopsy Market

List of Companies Mentioned in the Report:

  • Abbott Laboratories
  • AceCGT Life Science Limited
  • ADVI Health LLC
  • Amazon
  • Angle Plc
  • Apostle
  • AssureMDx
  • Astellas
  • AstraZeneca
  • Beckman Coulter
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioReference Laboratories
  • Biotime
  • Blue Cross Blue Shield of Illinois
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Caris Life Sciences, Inc.
  • Catalyst Pharmaceuticals
  • CellMax Life
  • Cerba HealthCare
  • Cirina, Ltd.
  • Clearbridge BioMedics
  • Clinical Genomics
  • Clovis Oncology
  • CORE Diagnostics
  • Daiichi Sankyo
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche AG
  • Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata Hospital
  • Foundation Medicine, Inc.
  • GATC Biotech AG
  • Grail
  • Guardant Health, Inc.
  • HansaBioMed Life Sciences Ltd.
  • HarlePhil Ventures
  • Illumina, Inc.
  • IPS Genomix
  • Janssen Diagnostics, LLC
  • Johnson & Johnson
  • Lab21 Clinical Laboratory
  • LabCorp
  • Maccura Biotechnology Co., Ltd.
  • MDxHealth SA
  • MedGenome
  • MediNcrease Health Plans, LLC
  • Menarini Silicon Biosystems, Inc.
  • Merck KGaA
  • Merck Serono
  • Miraca Life Sciences, Inc.
  • MVZ
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • NovioGendix Holding B.V.
  • Novogene Co. Ltd.
  • Oncocyte Corporation
  • OncoMed Pharmaceuticals
  • OPKO Health, Inc.
  • Pathway Genomics
  • PAXgene
  • Permanente Medical Group
  • Pfizer
  • Priority Health
  • QIAGEN N.V.
  • Roche Holdings AG
  • Silicon Biosystems
  • SoftBank
  • SouthGenetics, Inc.
  • Stratose, Inc.
  • Swift Biosciences, Inc.
  • Synlab Group's Labco Quality Diagnostics
  • Sysmex Inostics GmbH
  • Teneovita Medical Innovations, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • The European Health Centre (EHC) Innovation
  • TrovaGene, Inc.
  • Unilabs
  • VWR International, LLC
  • Wellmark, Inc.
  • List of Organisations Mentioned in the Report
  • Addario Lung Cancer Medical Institute
  • American Cancer Society
  • American Hospital Association
  • American Society of Clinical Oncologists
  • Catholic Health Initiatives Center for Translational Research
  • College of American Pathologists
  • Dana-Farber Cancer Institute
  • Duke University Health System
  • Ghent University
  • HIFU CLINIC Prostate Cancer Center
  • Horizon Blue Cross Blue Shield
  • Institut Gustave Roussy
  • International Agency for Research on Cancer
  • Istituto Diagnostico Varelli
  • Lurie Comprehensive Cancer Center of Northwestern University
  • Maastricht University
  • Mayo Clinic Center
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Center East Japan
  • National Center for Toxicological Research
  • National Health Laboratory
  • Netherlands Cancer Institute
  • Northwestern University
  • OHSU Knight Cancer Institute
  • Spanish National Cancer Research Center
  • The Christie Hospital
  • The University of Texas
  • UC San Diego Medical Center
  • University of California
  • University of Michigan Comprehensive Cancer Center
  • University of Texas Southwestern Medical Center
  • University of Tokyo
  • US Oncology Research
  • USC Norris Comprehensive Cancer Center
  • World Health Organization
  • Yale University School of Medicine
目次
Product Code: PHA0620

Title:
Global Liquid Biopsy Market Forecast to 2029
Instruments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres.

The global liquid biopsy market is estimated to reach $1,173.5m in 2019. The kits & reagents submarket holds the biggest share of the global liquid biopsy market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 180-page report you will receive 179 charts - all unavailable elsewhere.

The 180-page report provides clear detailed insight into the liquid biopsy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Liquid Biopsy Market forecast to 2029

Revenue forecasts for the Liquid Biopsy Market Forecast by Product to 2029:

  • Instruments
  • Kits & Reagents
  • Services

Each submarket is further segmented by regional market.

Revenue forecasts for the Liquid Biopsy Market Forecast by Sample to 2029:

  • Blood
  • Urine
  • Other Samples

Each submarket is further segmented by regional market.

Revenue forecasts for the Liquid Biopsy Market Forecast by Biomarker to 2029:

  • Circulating Tumor Cells (CTC)
  • Circulating Tumor DNA (CtDNA)
  • Exosomes
  • Other Biomarkers

Each submarket is further segmented by regional market.

Revenue forecasts for the Liquid Biopsy Market Forecast by Cancer to 2029:

  • Breast Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Lung Cancer
  • Prostate Cancer
  • Other Cancers

Each submarket is further segmented by regional market.

Revenue forecasts for the Liquid Biopsy Market Forecast by End-User to 2029:

  • Hospitals
  • Diagnostic Laboratories
  • Academic Institutions
  • Cancer Research Centres

Each submarket is further segmented by regional market.

Revenue forecasts for the Liquid Biopsy Market Forecast by Region to 2029:

North America:

  • U.S.
  • Canada
  • Mexico

Europe:

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia-Pacific:

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

LAMEA:

  • Brazil
  • Turkey
  • Venezuela
  • Saudi Arabia
  • Republic of South Africa
  • Rest of LAMEA

Profiles of the selected leading companies:

  • Abbott
  • Beckman Coulter
  • Biocept, Inc.
  • Bio-Rad Laboratories
  • Biotime
  • Caris Lifesciences
  • F. Hoffman-La Roche
  • Guardant Health, Inc.
  • Illumina, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems, Inc.
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Qiagen N.V.
  • Sysmex Inostics
  • Trovagene, Inc.

This report discusses Drivers, Restraints, Opportunities and Threats of the global liquid biopsy market

The report also includes a PESTLE Analysis of the Global Liquid Biopsy Market

Key questions answered by this report:

  • How is the Liquid Biopsy market evolving?
  • What are the drivers and restraints for the growth of the liquid biopsy market?
  • What are the market shares of each segment of the overall liquid biopsy market in 2018?
  • How will each liquid biopsy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each liquid biopsy submarket develop to 2029?
  • Which individual therapies will prevail and how will these shifts be responded to?
  • What will be the main driver for the overall market to 2029?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2019 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Liquid Biopsy Market. You find data, trends and predictions.

Buy our report today Global Liquid Biopsy Market Forecast to 2029:struments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Liquid Biopsy Market Overview
  • 1.2 Liquid Biopsy Market Definition & Scope
  • 1.3 Overview of Findings
  • 1.4 Structure of the Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 How This Report Delivers
  • 1.7 Who is This Report For?
  • 1.8 Methodology
    • 1.8.1 Primary Research
    • 1.8.2 Secondary Research
    • 1.8.3 Market Evaluation & Forecasting Methodology
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Liquid Biopsy Market Overview

  • 2.1 History of Liquid Biopsies
  • 2.2 Advantages of Liquid Biopsies
  • 2.3 Trends in Liquid Biopsy Market
    • 2.3.1 Companies Increasingly Focusing on Developing Biomarkers Detection Kits
    • 2.3.2 Emergence of Oncogenic Mutations Detection Platforms
    • 2.3.3 Rising Demand for Minimally Invasive Cancer Biomarkers Detecting Procedures
  • 2.4 Market Dynamics
    • 2.4.1 Drivers
      • 2.4.1.1 Rising incidence of cancer globally
      • 2.4.1.2 Increasing Rate of Aging Population
      • 2.4.1.3 Rising demand for safe and minimally invasive procedures
      • 2.4.1.4 Advantages of liquid biopsy
    • 2.4.2 Restraints
      • 2.4.2.1 Disparity in reimbursements
      • 2.4.2.2 Strict regulatory environment
    • 2.4.3 Opportunities:
      • 2.4.3.1 Increasing involvement of global market players through collaborations/agreements
      • 2.4.3.2 Progress in the development of liquid biopsy tests
  • 2.5 Global Liquid Biopsy Market: Revenue Forecast, 2018-2029
  • 2.6 Regulatory Landscape for Liquid Biopsies
  • 2.7 Latest developments in the liquid biopsy industry
    • 2.7.1 Emergence of artificial intelligence technologies is set to boost the liquid biopsy market
    • 2.7.2 Liquid biopsy is considered to be one of the most significant breakthrough treatments for cancer
    • 2.7.3 Multi-Target Liquid Biopsy would be a novel clinical test to watch out in 2019

3. Global Liquid Biopsy Market by Product Type: Market Forecast to 2029

  • 3.1 Global Liquid Biopsy Market, By Product Type, Revenue Forecast, 2018-2029
  • 3.2 Instruments Segment
    • 3.2.1 Global Liquid Biopsy Market, Instruments Segment Revenue Forecast, 2018-2029
  • 3.3 Kits & Reagents Segment
    • 3.3.1 Global Liquid Biopsy Market, Kits & Reagents Segment Revenue Forecast, 2018-2029
  • 3.4 Services Segment
    • 3.4.1 Global Liquid Biopsy Market, Services Segment Revenue Forecast, 2018-2029
  • 3.5 Market Share Analysis, by Product Type

4. Global Liquid Biopsy Market by Sample Type: Market Forecast to 2029

  • 4.1 Global Liquid Biopsy Market by Sample Type: Revenue Forecast to 2029
  • 4.2 Global Liquid Biopsy Market: Blood Sample Segment Revenue Forecast to 2029
  • 4.3 Global Liquid Biopsy Market: Urine Sample Segment Revenue Forecast to 2029
  • 4.4 Global Liquid Biopsy Market: Other Samples Revenue Forecast to 2029
  • 4.5 Market Share Analysis by Sample Type

5. Global Liquid Biopsy Market by Biomarker Type: Market Forecast to 2029

  • 5.1 Global Liquid Biopsy Market by Biomarker Type: Revenue Forecast to 2029
  • 5.2 Global Liquid Biopsy Market: Circulating Tumour Cell (CTC) Segment Revenue Forecast to 2029
  • 5.3 Global Liquid Biopsy Market: Circulating Tumour DNA (ctDNA) Segment Revenue Forecast to 2029
  • 5.4 Global Liquid Biopsy Market: Exosomes Segment Revenue Forecast to 2029
  • 5.5 Global Liquid Biopsy Market: Other Biomarkers Segment Revenue Forecast to 2029
  • 5.6 Market Share Analysis by Biomarker Type

6. Global Liquid Biopsy Market by Cancer Type: Market Forecast to 2029

  • 6.1 Global Liquid Biopsy Market by Cancer Type: Revenue Forecast to 2029
  • 6.2 Global Liquid Biopsy Market: Breast Cancer Segment Revenue Forecast to 2029
  • 6.3 Global Liquid Biopsy Market: Colorectal Cancer Segment Revenue Forecast to 2029
  • 6.4 Global Liquid Biopsy Market: Liver Cancer Segment Revenue Forecast to 2029
  • 6.5 Global Liquid Biopsy Market: Lung Cancer Segment Revenue Forecast to 2029
  • 6.6 Global Liquid Biopsy Market: Prostate Cancer Segment Revenue Forecast to 2029
  • 6.7 Global Liquid Biopsy Market: Other Cancers Segment Revenue Forecast to 2029
  • 6.8 Market Share Analysis by Cancer Type
  • 6.9 Comparative Incidence of Cancer by Region
  • 6.9.1 Incidence pattern of breast cancer across geographies
  • 6.9.1.1 Breast cancer incidence in Canada, 2016

7. Global Liquid Biopsy Market by End-User: Market Forecast to 2029

  • 7.1 Global Liquid Biopsy Market by End-User: Revenue Forecast to 2029
  • 7.2 Global Liquid Biopsy Market: Hospitals Segment Revenue Forecast to 2029
  • 7.3 Global Liquid Biopsy Market: Diagnostic Laboratories Segment Revenue Forecast to 2029
  • 7.4 Global Liquid Biopsy Market: Academic Institutions Segment Revenue Forecast to 2029
  • 7.5 Global Liquid Biopsy Market: Cancer Research Centres Segment Revenue Forecast to 2029
  • 7.6 Market Share Analysis by End-User

8. Global Liquid Biopsy Market by Leading Nationals: Market Forecast to 2029

  • 8.1 Global Liquid Biopsy Market by Leading Nationals: Revenue Forecast to 2029
  • 8.2 North America
    • 8.2.1 North America Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.2.2 North America Liquid Biopsy Market: Revenue Forecast by Country to 2029
    • 8.2.3 US Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.2.4 Canada Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.2.5 Mexico Liquid Biopsy Market: Revenue Forecast to 2029
  • 8.3 Europe
    • 8.3.1 Europe Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.3.2 Europe Liquid Biopsy Market: Revenue Forecast by Country to 2029
    • 8.3.3 Germany Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.3.4 France Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.3.5 United Kingdom Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.3.6 Italy Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.3.7 Spain Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.3.8 Russia Liquid Biopsy Market: Revenue Forecast to 2029
  • 8.4 Asia-Pacific
    • 8.4.1 Asia-Pacific Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.4.2 Asia-Pacific Liquid Biopsy Market: Revenue Forecast by Country to 2029
    • 8.4.3 Japan Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.4.4 China Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.4.5 Australia Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.4.6 South Korea Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.4.7 India Liquid Biopsy Market: Revenue Forecast to 2029
  • 8.5 LAMEA
    • 8.5.1 LAMEA Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.5.2 LAMEA Liquid Biopsy Market: Revenue Forecast by Country to 2029
    • 8.5.3 Brazil Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.5.4 Turkey Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.5.5 Venezuela Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.5.6 Saudi Arabia Liquid Biopsy Market: Revenue Forecast to 2029
    • 8.5.7 Republic of South Africa Liquid Biopsy Market: Revenue Forecast to 2029

9. Leading Companies in Liquid Biopsy Market

  • 9.1 Company Ranking: Liquid Biopsy Market
  • 9.2 Menarini Silicon Biosystems, Inc.
    • 9.2.1 Overview
    • 9.2.2 Technology
    • 9.2.3 Products
    • 9.2.4 Recent Strategic Developments
  • 9.3 MDxHealth SA
    • 9.3.1 Overview
    • 9.3.2 Financials
    • 9.3.3 Products
    • 9.3.4 Recent Strategic Developments
  • 9.4 Biocept, Inc.
    • 9.4.1 Overview
    • 9.4.2 Financials
    • 9.4.3 Products
    • 9.4.4 Recent Strategic Developments
  • 9.5 Trovagene, Inc.
    • 9.5.1 Overview
    • 9.5.2 Technology
    • 9.5.3 Financials
    • 9.5.4 Products
    • 9.5.5 Recent Strategic Developments
  • 9.6 Sysmex Inostics GmbH (A Subsidiary of Sysmex Corporation)
    • 9.6.1 Overview
    • 9.6.2 Technology
    • 9.6.3 Products
    • 9.6.4 Financials
    • 9.6.5 Recent Developments
  • 9.7 F. Hoffmann-La Roche AG
    • 9.7.1 Overview
    • 9.7.2 Financials
    • 9.7.3 Products
    • 9.7.4 Recent Strategic Developments
  • 9.8 Bio-Rad Laboratories, Inc.
    • 9.8.1 Overview
    • 9.8.2 Financials
    • 9.8.3 Products
    • 9.8.4 Recent Strategic Developments
  • 9.9 Guardant Health, Inc.
    • 9.9.1 Overview
    • 9.9.2 Products
    • 9.9.3 Recent Strategic Developments
  • 9.10 Illumina, Inc.
    • 9.10.1 Overview
    • 9.10.2 Financials
    • 9.10.3 Recent Strategic Developments
  • 9.11 Myriad Genetics, Inc.
    • 9.11.1 Overview
    • 9.11.2 Financials
    • 9.11.3 Products
    • 9.11.4 Recent Strategic Developments
  • 9.12 Qiagen N.V.
    • 9.12.1 Overview
    • 9.12.2 Financials
    • 9.12.3 Products
    • 9.12.4 Recent Strategic Developments
  • 9.13 Biotime (Oncocyte Corporation)
    • 9.13.1 Overview
    • 9.13.2 Financials
    • 9.13.3 Products
  • 9.14 Abbott
    • 9.14.1 Overview
    • 9.14.2 Financials
    • 9.14.3 Recent Strategic Developments
  • 9.15 Beckman Coulter (Danaher Corporation)
    • 9.15.1 Overview
    • 9.15.2 Financials
    • 9.15.3 Products
    • 9.15.4 Recent Strategic Developments
  • 9.16 Caris Life Sciences
    • 9.16.1 Overview
    • 9.16.2 Products
  • 9.17 OPKO Health, Inc.
    • 9.17.1 Overview
    • 9.17.2 Financials
    • 9.17.3 Products
    • 9.17.4 Recent Strategic Developments

10. Qualitative Analysis of the Liquid Biopsy Market

  • 10.1 PESTEL Analysis of the Liquid Biopsy Market
    • 10.1.1 Political
      • 10.1.1.1 Regulatory Bodies:
      • 10.1.1.2 Insurance / Reimbursement:
    • 10.1.2 Economic
    • 10.1.3 Social
    • 10.1.4 Environmental Factors
    • 10.1.5 Technological
      • 10.1.5.1 Decline in use of Old Technologies and Advent of New Technologies
      • 10.1.5.2 Early Stage Diagnosis of Cancer with Liquid Biopsies
      • 10.1.5.3 Improved Liquid Biopsy Techniques
      • 10.1.5.4 Comparison with Tissue Sampling
      • 10.1.5.5 Cost Reductions and Time Saving with Liquid Biopsies
    • 10.1.6 Legal
      • 10.1.6.1 Regulatory Science Challenge
      • 10.1.6.2 FDA
      • 10.1.6.3 Lawsuits and Litigations

11. Conclusion

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.